Added to YB: 2025-08-12
Pitch date: 2025-08-08
LLY [bullish]
Eli Lilly and Company
+63.85%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$627.11
Price Target
1.0K (-3%)
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
turnaround
Deep Dive: Eli Lilly (LLY)
LLY: 14% single-day collapse after orforglipron Phase III results fell short of expectations (12.4% vs 15% weight loss). Despite miss, growth story intact with tirzepatide franchise driving 38% YoY revenue growth. Bull case: dominant GLP-1 position, Alzheimer's potential, robust pipeline including retatrutide. $1,000 price target by mid-2026. Support at $540-550 critical.
Read full article (17 min)